Hypersensitivity Pneumonitis in Progressive Fibrosing Interstitial Lung Disease
Fibrotic hypersensitivity pneumonitis (HP) does not always remain stable. When it follows a progressive fibrosing course, a distinct therapeutic approach is warranted — one that goes beyond antigen avoidance alone.
Clinical Scenario
Progressive fibrosing interstitial lung disease (ILD); fibrotic hypersensitivity pneumonitis with a progressive phenotype. Anti-fibrotic therapy should be considered in patients with progressive fibrosing ILD.
Treatment Approach (partial)
Management centres on anti-fibrotic therapy — an agent licensed in several countries specifically for fibrosing ILDs with a progressive phenotype. The complete evidence-based protocol with full details is available below.
References
DOI: 10.1183/16000617.0169-2021
- Anti-fibrotic therapy should be considered in patients with progressive fibrosing ILD.
- Nintedanib, a tyrosine kinase inhibitor, is an approved treatment option for fibrotic HP with a progressive phenotype.
- Nintedanib, an intracellular inhibitor of tyrosine kinases, has been licensed in several countries for the treatment of chronic fibrosing ILDs with a progressive phenotype.
View source ↗